PI3K/mTOR Inhibitor-13 sodium

Name: PI3K/mTOR Inhibitor-13 sodium
Brand: MedChemExpress
SKU: HY-153120A
Rating: 4.5 (1 reviews)

Cat. No.: HY-153120A Purity: 98.13%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF).

For research use only. We do not sell to patients.

PI3K/mTOR Inhibitor-13 sodium Chemical Structure

CAS No. : 2361009-23-4

Size	Price	Stock	Quantity
5 mg	USD 420	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 680	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1380	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 2200	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 3500	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of PI3K/mTOR Inhibitor-13 sodium:

PI3K/mTOR Inhibitor-13 Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All mTOR Isoform Specific Products:

View All Isoforms

mTOR mTORC1 mTORC2

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

PI3K/mTOR Inhibitor-13 sodium (Compound A) (0-2 µM; 48 h) inhibits the proliferation of HFL1 cells with dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	HFL1 cells.
Concentration:	0, 0.03125, 0.0125, 0.025, 0.05, 0.0625, 0.1, 0.125, 0.2, 0.25, 0.4, 0.5, 1 and 2 µM.
Incubation Time:	48 h.
Result:	Showed inhibitory for HFL1 cells.

Western Blot Analysis^[1]

Cell Line:	HFL1 cells.
Concentration:	200 nM.
Incubation Time:	48 h.
Result:	Increased the expression of α-SMA/Tubulin.

In Vivo

Pharmacokinetic (PK) parameters of PI3K/mTOR Inhibitor-13 sodium^[2]

Species	Administration manner	Dose (mg/kg)	T_1/2 (h)	AUC_last (ng•h/mL)	Cl/F (L/h/kg)	V_ss (L/kg)	F (%)
Rat	Intravenous injection	2	2.77	7069	0.29	0.85	94.75
Mice	Intravenous injection	1	5.45	57059	0.02	0.13	79.3
Dog	Intravenous injection	1	0.67	3672	0.27	0.23	108.5
Monkey	Intravenous injection	1	9.70	5978	0.16	0.92	59.8

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

464.40

Formula

C₂₀H₁₃F₂N₅NaO₃S

CAS No.

2361009-23-4

Appearance

Solid

Color

White to off-white

SMILES

N#CC1=C2C=C(C3=CC(NS(=O)(C4=CC=C(C=C4F)F)=O)=C(OC)N=C3)C=CN2N=C1.[Na]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (215.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1533 mL	10.7666 mL	21.5332 mL
5 mM	0.4307 mL	2.1533 mL	4.3066 mL
10 mM	0.2153 mL	1.0767 mL	2.1533 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.38 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.38 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 2.5 mg/mL (5.38 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.13%

Select Batch:

Data Sheet (282 KB) SDS (251 KB)

COA (259 KB) HNMR (139 KB) RP-HPLC (139 KB) LCMS (232 KB)

Handling Instructions (2659 KB)

References

[1]. Cao S, et al. Pharmaceutical combination or pharmaceutical composition for treatment of fibrotic diseases. World Intellectual Property Organization. WO2020078445.

[2]. Xi N, et al. Aromatic heterocyclic compounds, pharmaceutical composition containing compounds and application of pharmaceutical composition.China.CN103965199.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1533 mL	10.7666 mL	21.5332 mL	53.8329 mL
	5 mM	0.4307 mL	2.1533 mL	4.3066 mL	10.7666 mL
	10 mM	0.2153 mL	1.0767 mL	2.1533 mL	5.3833 mL
	15 mM	0.1436 mL	0.7178 mL	1.4355 mL	3.5889 mL
	20 mM	0.1077 mL	0.5383 mL	1.0767 mL	2.6916 mL
	25 mM	0.0861 mL	0.4307 mL	0.8613 mL	2.1533 mL
	30 mM	0.0718 mL	0.3589 mL	0.7178 mL	1.7944 mL
	40 mM	0.0538 mL	0.2692 mL	0.5383 mL	1.3458 mL
	50 mM	0.0431 mL	0.2153 mL	0.4307 mL	1.0767 mL
	60 mM	0.0359 mL	0.1794 mL	0.3589 mL	0.8972 mL
	80 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6729 mL
	100 mM	0.0215 mL	0.1077 mL	0.2153 mL	0.5383 mL